Abstract
Current Medicinal Chemistry - Anti-Cancer Agents
Title: Subject Index To Volume 2
Volume: 3Issue: 1
Author(s): Bentham Science Publishers
Affiliation:
Abstract:
Export Options
About this article
Cite this article as:
Bentham Science Publishers , Subject Index To Volume 2, Current Medicinal Chemistry - Anti-Cancer Agents 2003; 3 (1) .https://dx.doi.org/10.2174/1568011033353588
| DOI https://dx.doi.org/10.2174/1568011033353588 | Print ISSN 1568-0118 |
| Publisher Name Bentham Science Publisher | Online ISSN 1875-5968 |
Related Journals
Related Books
Nanomaterials in Glioblastoma Research, Diagnosis and Therapy
Advancements in Cancer Research: Exploring Diagnostics and Therapeutic Breakthroughs
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Cancer Genes
Cancer Medicine in an Ayurvedic Perspective: A Critical Overview
Cancer Genes
Anticancer Immunity: Reviewing the Potential of Probiotics
Probiotics in Anticancer Immunity
Phytonutrients in the Treatment of Gastrointestinal Cancer
8Related Articles
- Melatonin as a Promising Agent for Cancer Treatment: Insights intoits Effects on the Wnt/beta-catenin Signaling Pathway
Current Medicinal ChemistryInduction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design T Cell Polarization and the Formation of Immunological Synapses: From Antigen Recognition to Virus Spread
Current Immunology Reviews (Discontinued)The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug TargetsChemotherapy Resistance Molecular Mechanism in Small Cell Lung Cancer
Current Molecular MedicineLKB1 Mutations Enhance Radiosensitivity in Non-Small Cell Lung Cancer Cells by Inducing G2/M Cell Cycle Phase Arrest
Current Molecular Medicine Metabolism of Δ³-Carene by Human Cytochrome P450 Enzymes: Identification and Characterization of Two New Metabolites
Current Drug MetabolismImplications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug MetabolismNovel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects
Current Pharmaceutical DesignColon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs
Anti-Cancer Agents in Medicinal ChemistryIron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal ChemistryPharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical DesignGenome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design Recent Advances in Anticancer Chemotherapeutics based upon Azepine Scaffold
Anti-Cancer Agents in Medicinal ChemistryCarbonic Anhydrase Based Biomarkers: Potential Application in Human Health and Environmental Sciences
Current Biomarkers (Discontinued) Experience with Indium-111 and Yttrium-90-Labeled Somatostatin Analogs
Current Pharmaceutical Design Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal ChemistrySmall-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Current Drug Targets What Have We Learned from the Novel Human Cytochromes P450 Hidden in the Databases?
Current Genomics
[8]ページ先頭